Clinical Case Challenge: Can You Effectively Manage Patients With NF1-Associated Tumors?

Stratum 3 results from the Pediatric Brain Tumor Consortium (PBTC) multicenter, phase 2 study demonstrated that patients with any neurofibromatosis type 1 (NF1)-associated pediatric low-grade glioma had a 40% sustained partial response at the median follow-up of 48.6 months while 17 patients had no progression when treated with which agent?

A phase 2 trial of which BRAF/MEK combination showed improved response rates vs chemotherapy in patients with BRAF V600 mutant low-grade gliomas?